Aptus Pharma Discloses Promoter Share Purchases
Aptus Pharma Limited disclosed multiple inter-se share transfers among its promoters, executed off-market on the BSE on May 11, 2026. The transactions involved purchases by several group members and a sale by Chattrabhujat Butani, with values ranging from ₹35,00,000 to ₹4,94,00,000. The company confirmed compliance with SEBI regulations and reported no derivative trading activities by the promoters.
*this image is generated using AI for illustrative purposes only.
Aptus Pharma Limited has disclosed a series of transactions involving the transfer of equity shares among members of its promoter group. The company submitted these details to the BSE in compliance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosures were made by Tejash Maheshchandra Hathi, the Managing Director of the company.
Transaction Details
The transactions were classified as off-market inter-se transfers among the promoter group. These trades were executed on the BSE on May 11, 2026. The company received intimations regarding these changes in shareholding on May 13, 2026. The disclosures detail the acquisition and disposal of shares by various promoters, altering their respective percentage holdings in the pharmaceutical company.
Changes in Promoter Holdings
The disclosures outline the specific number of shares bought and sold by individual promoters, along with the corresponding values and the resulting post-transaction shareholding percentages. The table below summarizes the key changes in the shareholding patterns of the identified promoters.
| Promoter Name | Type | Shares Transacted | Transaction Value | Pre-Transaction Holding | Post-Transaction Holding |
|---|---|---|---|---|---|
| Chattrabhujat Butani | Sale | 124000 | 43400000 | 2,25,000 (3.28%) | 101000 (1.47%) |
| Gaurang Rameshchandra Thakker | Purchase | 18000 | 6300000 | 575000 (8.38%) | 593000 (8.64%) |
| Ghanshyam Vinubhai Pansuriya | Purchase | 14000 | 49000000 | 350000 (5.10%) | 364000 (5.31%) |
| Mr. Kapil Chandarana | Purchase | 10000 | 3500000 | 775000 (11.30%) | 785000 (11.44%) |
| Kripaliben Mayank Thakker | Purchase | 18000 | 6300000 | 575000 (8.38%) | 593000 (8.64%) |
| Milly Chetan Lalseta | Purchase | 18000 | 6300000 | 575000 (8.38%) | 593000 (8.64%) |
| Riddhish Natwarlal Tanna | Purchase | 18000 | 6300000 | 575000 (8.38%) | 593000 (8.64%) |
| Mr. Tejasbhai Hathi | Purchase | 10000 | 3500000 | 775000 (11.30%) | 785000 (11.44%) |
| Kunjal Piyushbhai Unadkat | Purchase | 18000 | 6300000 | 575000 (8.38%) | 593000 (8.64%) |
Regulatory Compliance
The company confirmed that there were no trades in derivatives by the promoters or their immediate relatives during the period under review. The disclosures were signed and submitted by the Managing Director, Tejash Maheshchandra Hathi, on May 15, 2026, from Rajkot. The filings ensure compliance with the continual disclosure requirements mandated by the market regulator for listed entities.
How might the redistribution of shareholding among Aptus Pharma's promoter group affect the company's corporate governance structure and decision-making dynamics going forward?
Could this inter-se transfer of shares signal a potential consolidation of control ahead of a strategic corporate action such as a merger, acquisition, or fundraising round?
What impact, if any, might the significant reduction in Chattrabhuijhat Butani's stake from 3.28% to 1.47% have on investor sentiment and the stock's liquidity on BSE?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
